N-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)acetamide | 63122-46-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)acetamide
• 英文别名: 4-Acetamido-s-hydrindacen
• CAS: 63122-46-3
• 化学式: C₁₄H₁₇NO
• 分子量: 215.295
• InChiKey: FSJDNYQLNNWHJW-UHFFFAOYSA-N

物化性质

• 熔点：
  249-250 °C(Solv: benzene (71-43-2))
• 沸点：
  399.4±42.0 °C(Predicted)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)acetamide 在 磷酸 作用下， 生成 4-Benzylidenamino-s-hydrindacen
  参考文献：
  名称：

  4-Amino-s-hydrindacene and derivatives: Synthesis and pharmacological screening

  摘要：

  DOI：

  10.1135/cccc19771992
• 作为产物：
  描述：

  4-Acetyl-s-hydrindacen-oxim 在 三氟乙酸 作用下， 生成 N-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)acetamide
  参考文献：
  名称：

  4-Amino-s-hydrindacene and derivatives: Synthesis and pharmacological screening

  摘要：

  DOI：

  10.1135/cccc19771992

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：INFLAZOME LTD

  公开号：WO2019211463A1

  公开（公告）日：2019-11-07

  The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as -NH-, with a cyclic group which in turn is substituted at the α-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

  本发明涉及取代的含氮杂环化合物，例如磺酰基三唑，其中杂环环进一步取代，可选地通过类似-NH-的连接基团，与环状基团相连，该环状基团在α-位置进一步取代。本发明还涉及相关的盐、溶剂合物、前药和药物组合物，以及这些化合物在治疗和预防医学疾病和疾病中的使用，尤其是通过NLRP3抑制。
• [EN] NLRP3 INHIBITORS<br/>[FR] INHIBITEURS DE NLRP3
  申请人：INFLAZOME LTD

  公开号：WO2020104657A1

  公开（公告）日：2020-05-28

  The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.

  本申请涉及具有NLRP3抑制活性的化合物及其相关盐、溶剂合物、前药和药物组合物。本申请进一步涉及利用这些化合物在治疗和预防医学疾病和疾病中的应用，尤其是通过NLRP3抑制。
• [EN] FUSED 1,2 THIAZOLES AND 1,2 THIAZINES WHICH ACT AS NL3P3 MODULATORS<br/>[FR] 1,2-THIAZOLES ET 1,2 THIAZINES FUSIONNÉS QUI AGISSENT EN TANT QUE MODULATEURS DE NL3P3
  申请人：AC IMMUNE SA

  公开号：WO2020254697A1

  公开（公告）日：2020-12-24

  The present invention relates to novel compounds (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a component of the inflammasome pathway. In particular, the component of the inflammasome pathway is NLRP3 inflammasome. More particularly, the compounds of the present invention have the capability to inhibit the NLRP3 inflammasome. Further, the compounds of the present invention modulate, in particular, decrease IL-1 beta and/or IL-18 levels.

  本发明涉及新型化合物（I），可用于治疗、缓解或预防一组疾病、障碍和异常，这些疾病、障碍和异常对炎症小体通路的激活的调节或抑制具有响应性。特别地，炎症小体通路的组分是NLRP3炎症小体。更具体地，本发明的化合物具有抑制NLRP3炎症小体的能力。此外，本发明的化合物特别是调节，特别是降低IL-1β和/或IL-18水平。
• [EN] NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE SULFONYLURÉES SUBSTITUÉS
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2020148619A1

  公开（公告）日：2020-07-23

  The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1β activity is implicated.

  本发明涉及一般式（I）的新型杂环化合物及其药学上可接受的盐、药学上可接受的溶剂、对映异构体、顺反异构体和多晶形。本发明还涉及制备本发明化合物的方法、含有该化合物的制药组合物及其作为NOD样受体家族（NLR）蛋白NLRP3调节剂的化合物的用途。因此，本发明涉及新型NLRP3调节剂以及在治疗与白细胞介素1β活性有关的疾病或病况中使用新型抑制剂化合物的用途。
• Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
  申请人：Pfizer Inc

  公开号：US06433009B1

  公开（公告）日：2002-08-13

  A compound of the formula wherein R1 and R2 are as defined above, useful in the treatment and condition selected from the group consisting of meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation, tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimers disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

  一种化合物的公式，其中R1和R2的定义如上所述，可用于治疗和改善选择的病症包括脑膜炎和输卵管炎、脓毒症、弥漫性血管内凝血、成人呼吸窘迫综合症、急性或慢性炎症、关节炎、胆管炎、结肠炎、脑炎、心内膜炎、肾小球肾炎、肝炎、心肌炎、胰腺炎、心包炎、再灌注损伤、血管炎、急性和迟发性过敏、移植排斥和移植物抗宿主病、自身免疫疾病，包括1型糖尿病和多发性硬化症、牙周病、间质性肺纤维化、肝硬化、全身性硬化、瘢痕形成、产生IL-1作为自分泌生长因子的肿瘤、消瘦症、阿尔茨海默病、振动伤害、抑郁症、动脉粥样硬化、哺乳动物，包括人类的骨质疏松症。